News

BioAxis Research


News


2018


Further publication on drug design workflows as part of 3D-e-Chem consortium work.


Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers


Q3-4 2017


The International Chemical Design Course at RadboudUMC has taken place, including lectures and hands-on KNIME practicals given by BioAxis Research and the 3D-e-Chem consortium.


Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers


Q2 2017


BioAxis Research has recieved subsidy funding for a project "Multi-Target Metabolic Syndrom Drugs" (STIMULUS funding, MKB Innovatiestimulering topsectoren Zuid-Nederland).


Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers


Q1 2017


The 3D-e-Chem consortium, a team of cheminformatics and bioinformatics researchers from Centre for Molecular and Biomolecular Informatics, Netherlands eScience Center, BioAxis Research, and Vrije Universiteit Amsterdam have developed a freely available virtual machine to enable computer-aided drug design. The 3D-e-Chem software tools and virtual machine are described in a recent publication in the Journal of Chemical Modeling and Information and the computational building blocks (nodes) that enable researchers to design their own drug discovery workflows are now incorporated in KNIME, the leading open data analytics platform.


Tools and worflows developed by the  3D-e-Chem consortium were also presented and a workshop given at the KNIME Spring Summit in Berlin


Q4 2016


COILED collaboration funded by an EFRO grant begins








Collaboration work continues with small biotechs/large pharma/European screening centers


Q3 2016


Collaboration work continues with small biotechs/large pharma/European screening centers


3D-e-Chem VM and Knime nodes updated


Q1/Q2 2016


3d-e-Chem poster presented at Knime Spring Summit detailing progress on 3d-e-Chem Virtual Machine and Knime nodes



Ongoing collaborations continue with small biotechs are extended. New collobrations with Big Pharma begun




Q3/Q4 2015



Chemical Analytics Platfrom made available


Thanks to work performed by Stefan Verhoeven at the Netherland eScience center, a Vitual MAchine encompassing the work performed on the Chemical Analytics Platform project is now available on Github

https://github.com/NLeSC/Chemical-Analytics-Platform


Ongoing collaborations continue, are extended


Q1/Q2 2015


Ongoing collaborations continue, are extended


Q4 2014


Netherlands e-science center project "3D-e-Chem: Integrated eScience workflow to translate biological and chemical data into structure-based protein-ligand polypharmacology prediction", headed by Dr. C. de Graaf, (VU University Amsterdam) involves BioAxis Research (Link to VU News item, Dec 17 2014).



October 2nd, 2014 Exclusive R&D collaboration BioAxis Research and Okklo Life Science


Today BioAxis Research and Okklo Life Sciences have entered into an exclusive collaboration for R&D projects.

Their OCTOPlex technology contributes to the rapid development of specific sugar molecules, cyclodextrins, as potential treatment for various diseases.


BioAxis Research BV and Okklo Life Sciences BV have unique expertise on the design and development of cyclodextrin-based medicines. Cyclodextrins are ring-shaped sugar molecules with many promising features for development of new treatments, including therapies for rare (orphan) diseases. With the OCTOPlex technology, Okklo Life Sciences and BioAxis can rapidly design and optimize these molecules and develop these into potential therapeutics. In addition, the technology enables the design of novel cyclodextrins that can ‘inactivate’ a wide variety of drugs or harmful biological metabolites.

A first project will be initiated in the coming weeks, and other projects are planned for early 2015.


“With this agreement we strengthen our collaboration, and increase the capabilities of the technology. By working together, we will be able to more rapidly and effectively design and deliver drug candidates with the appropriate properties “ according to Ross McGuire, managing director of BioAxis Research.”We have successfully collaborated in the past and are very keen to demonstrate the strength of this combination again” said Daniel Zollinger, co-founder and managing director of Okklo Life Sciences.


BioAxis Research BV and Okklo Life Sciences BV are privately held companies, located at the Pivot Park in Oss, The Netherlands. Both enterprises have their roots in the former R&D organization of Organon/MSD and were involved in the development and approval of the first cyclodextrin-based drug in 2008.


Ongoing collaborations continue, are extended



Q3 2014


eScience Pathfinding project: "Chemical Analytics Platform" BioAxis/RadboudUMC (Prof G Vriend).

BioAxis Research involved in delivering the cheminformatics element of this project, using Open source relational databases, cheminformatics tools and analytics workflow management tools.


Ongoing collaborations continue, are extended


Publications updated

See Publications page


Q2 2014 Ongoing collaborations continue, are extended


Q1 2014 Ongoing collaborations continue, are extended


December 2013

Publications updated


See Publications page



November 2013

Collboration with Okklo Announced


Publications updated


See Publications page



September 2013

BioAxis Research begins collaboration with a second European screening centre, extends other collaboratiions


BioAxis Research has begun working with another European screening centre, providing cheminformatics analyses and services. Work continues with existing clients, extensions to collaboration agreements having been made



July 2013

BioAxis Research signs NDA, begins collaboration


BioAxis Research has signed further confidentiality agreements with a European research consortium and has begun exploratory collaborations



July 2013

Publications updated


See Publications page



Mar 2013

Bioaxis Research extends agreement



BioAxis and a small biotech partner have agreed to extend an ongoing collaboration for a further period



December 2012

BioAxis Research Agreement with Vivenics


BioAxis and Vivenics have entered an agreed working arrangement concerning areas of common interest in infrastructure and workflow tools, details not disclosed



May 2012

BioAxis Research extends collaborations with 2 partners


BioAxis has extended a collaboration with one public:private group for a fixed period, while another commercial parter has extended an ongoing collaboration



April 2012

BioAxis Research Radboud University


R. McGuire is now offically associated with the UMC St Radboud Nijmegen Centre for Molecular Life Sciences



April 2012

BioAxis Research Moves to Oss Life Science Park


BioAxis Research has moved into offices in the Oss Life Science park, as of 2 April 2012.

 


March 2012

Publications updated


BioAxis Research has contributed to recent publications - see publications page.

 


October 2011

BioAxis Research signs CDA's, begins collaborations


BioAxis Research has signed a number of confidentiallity agreements with various European research groups and has also concluded negotiations to collaborate with and perform work for a number of research organizations.



September 15th 2011

BioAxis Research presents at 9th Annual World Pharmaceutical IT Congress


BioAxis Research gave an invited presentation on Open Source Cheminformatics and IT in Discovery research at the 9th Annual World Pharmaceutical IT Congress, London


October - November 2011

BioAxis Research further 2011 publications accepted


The latest publication to be accepted is a review on structure-based pharmacophores, co-authored with colleagues from MSD and Dutch academia, recently accepted for publication in MedChemComm. Recent publications will be listed in the publications page



October 2011

BioAxis Research operational


BioAxis Research was launched officially in October 2011. BioAxis Research BV is a privately funded start-up, founded by Ross McGuire, former head of in silico Drug Design, MSD Oss. The company has been in preparation for a few weeks and is already in discussions with potential partners



Copyright © 2011-2016 All Rights Reserved